Background: Resistant hypertension is a common medical challenge facing clinicians and specialists. Although, the prevalence is currently unknown but various clinical trials have suggested that this problem is not rare. Resistant hypertension is blood pressure that remains above goal despite the use of at least three antihypertensive agents including a diuretic. It is a subtype of hypertension that increases the risk of cardiovascular, cerebrovascular and kidney disease. However, it is important to distinguish between pseudo-resistant hypertension and apparent hypertension from true resistant hypertension as they are often misdiagnosed.
Objectives: This review focuses on resistant hypertension, its pathophysiology and established therapy.
Methodology: Relevant articles used for this review covered a period of 2008-2022 using search engines and databases including PubMed, Scopus, Web of Science, and Google Scholar.
Main observation: Evaluation of patients with true resistant hypertension includes appropriate blood pressure measurement, screening for causes of secondary hypertension and screening for interfering medications. Management of resistant hypertension that has proved successful includes non-pharmacological approach like lifestyle modification and optimization of pharmacological agents, often including the use of mineralocorticoid receptor antagonist.
Conclusion: Considering the future management of resistant hypertension, a bunch of new device-based therapies are under effective development. Of these, renal denervation and carotid baroreflex activation are two potential devices for the significant reduction of blood pressure. However, further study is necessary before these devices can be approved for the routine treatment of resistant hypertension.
Keywords: Aldosterone; Cardiovascular disease; Resistant Hypertension; Therapy.
2. Kjeldsen SE. Hypertension and cardiovascular risk: General aspects. Pharmacol Res 2018; 129:95-99. https://doi.org/10.1016/j.phrs.2017.11.003
3. Alawode DI, Asiwe JN, Moke EG, Okonofua DE, Sanusi KO, Adagbada EO, et al. The Effect of Ethanol Leaf Extract of Cnidosculus Aconitifolius on Cardiorenal Functions in Hypertensive and Normotensive Male Wistar Rats. Int J Nutr Sci 2021; 6(3):155-160.
4. Zhang ZY, Yu YL, Asayama K, Hansen TW, Maestre GE, Staessen JA. Starting Antihypertensive Drug Treatment with Combination Therapy: Controversies in Hypertension - Con Side of the Argument. Hypertension 2021; 77(3):788-798. https://doi.org/10.1161/HYPERTENSIONAHA.120.12858
5. Yaxley JP, Thambar SV. Resistant hypertension: an approach to management in primary care. J Family Med Prim Care 2015; 4(2):193-199. https://doi.org/10.4103/2249-4863.154630
6. Carey RM. Special Article - The management of resistant hypertension: A 2020 update. Prog Cardiovasc Dis 2020; 63(5):662-670. https://doi.org/10.1016/j.pcad.2020.08.001
7. Acelajado MC, Hughes ZH, Oparil S, Calhoun DA. Treatment of Resistant and Refractory Hypertension. Circ Res 2019; 124(7):1061-1070. https://doi.org/10.1161/CIRCRESAHA.118.312156
8. Bhatt H, Siddiqui M, Judd E, Oparil S, Calhoun D. Prevalence of pseudoresistant hypertension due to inaccurate blood pressure measurement. J Am Soc Hypertens 2016; 10(6):493-9. https://doi.org/10.1016/j.jash.2016.03.186
9. Zanatta JMM, Cosenso-Martin LN, da Silva Lopes V, Roma Uyemura JR, Polegati Santos AM, Paz Landim MI, et al. Evidence of Nonadherence in Cases of Pseudoresistant Hypertension. Integr Blood Press Control 2021; 14:9-17. https://doi.org/10.2147/IBPC.S264057
10. Nuredini G, Saunders A, Rajkumar C, Okorie M. Current status of white coat hypertension: where are we? Ther Adv Cardiovasc Dis 2020; 14:1753944720931637. https://doi.org/10.1177/1753944720931637
11. Khanra D, Duggal B. Pseudo-resistance, resistant and refractory hypertension: The good, the bad and the ugly. J Pract Cardiovasc Sci 2019; 5:76-80. https://doi.org/10.4103/jpcs.jpcs_31_19
12. Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012; 125(13):1635-42. https://doi.org/10.1161/CIRCULATIONAHA.111.068064
13. Cai A, Calhoun DA. Resistant Hypertension: An Update of Experimental and Clinical Findings. Hypertension 2017; 70(1):5-9. https://doi.org/10.1161/HYPERTENSIONAHA.117.08929
14. Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective. Lancet 2014; 383(9921): 999-1008. https://doi.org/10.1016/S0140-6736(13)61752-3
15. Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol 2020; 16(4):223-237. https://doi.org/10.1038/s41581-019-0244-2
16. Benetos A, Petrovic M, Strandberg T. Hypertension Management in Older and Frail Older Patients. Circ Res 2019; 124(7):1045-1060. https://doi.org/10.1161/CIRCRESAHA.118.313236
17. Te Riet L, van Esch JHM, Roks AJM, van den Meiracker AH, Danser AHJ. Hypertension: renin-angiotensin-aldosterone system alterations. Circ Res 2015; 116:960-75. https://doi.org/10.1161/CIRCRESAHA.116.303587
18. Grillo A, Salvi L, Coruzzi P, Salvi P, Parati G. Sodium Intake and Hypertension. Nutrients 2019; 11(9):1970. https://doi.org/10.3390/nu11091970
19. Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, Pimenta E, Aban I, Oparil S, et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 2008; 168(11):1159-64. https://doi.org/10.1001/archinte.168.11.1159
20. Martins LC, Figueiredo VN, Quinaglia T, Boer-Martins L, Yugar-Toledo JC, Martin JF, et al. Characteristics of resistant hypertension: ageing, body mass index, hyperaldosteronism, cardiac hypertrophy and vascular stiffness. J Hum Hypertens. 2011; 25(9):532-8. https://doi.org/10.1038/jhh.2010.95
21. Pathan MK, Cohen DL. Resistant Hypertension: Where are We Now and Where Do We Go from Here? Integr Blood Press Control 2020; 13:83-93.
22. Gino Seravalle, Guido Grassi. Sympathetic nervous system and hypertension: New evidences. Autonomic Neuroscience 2022; 238:102954. https://doi.org/10.1016/j.autneu.2022.102954
23. Oliveras, A., de la Sierra, A. Resistant hypertension: patient characteristics, risk factors, co-morbidities and outcomes. J Hum Hypertens 2014; 28:213-217. https://doi.org/10.1038/jhh.2013.77
24. Santos RAS, Oudit GY, Verano-Braga T, Canta G, Steckelings UM, Bader M. The renin-angiotensin system: going beyond the classical paradigms. Am J Physiol Heart Circ Physiol 2019; 316(5):H958-H970. https://doi.org/10.1152/ajpheart.00723.2018
25. Dudoignon E, Dépret F, Legrand M. Is the Renin-Angiotensin-Aldosterone System Good for the Kidney in Acute Settings? Nephron 2019; 143(3):179-183. https://doi.org/10.1159/000499940
26. Arendse LB, Danser AHJ, Poglitsch M, Touyz RM, Burnett JC Jr, Llorens-Cortes C, et al. Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure. Pharmacol Rev 2019; 71(4):539-570. https://doi.org/10.1124/pr.118.017129
27. Muñoz-Durango N, Fuentes CA, Castillo AE, González-Gómez LM, Vecchiola A, Fardella CE, et al. Role of the Renin-Angiotensin-Aldosterone System beyond Blood Pressure Regulation: Molecular and Cellular Mechanisms Involved in End-Organ Damage during Arterial Hypertension. Int J Mol Sci 2016; 17(7):797. https://doi.org/10.3390/ijms17070797
28. Kaczmarski KR, Sozio SM, Chen J, Sang Y, Shafi T. Resistant hypertension and cardiovascular disease mortality in the US: results from the National Health and Nutrition Examination Survey (NHANES). BMC Nephrol 2019; 20(1):138. https://doi.org/10.1186/s12882-019-1315-0
29. de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011; 57(5):898-902. https://doi.org/10.1161/HYPERTENSIONAHA.110.168948
30. Jaffe G, Gray Z, Krishnan G, Stedman M, Zheng Y, Han J, et al. Screening rates for primary aldosteronism in resistant hypertension: A cohort study. Hypertension 2020; 75(3):650-659. https://doi.org/10.1161/HYPERTENSIONAHA.119.14359
31. Calhoun DA. Hyperaldosteronism as a common cause of resistant hypertension. Annu Rev Med 2013; 64:233-47. https://doi.org/10.1146/annurev-med-042711-135929
32. Stavropoulos K, Imprialos KP, Patoulias D, Katsimardou A, Doumas M. Impact of Primary Aldosteronism in Resistant Hypertension. Curr Hypertens Rep 2022; Ahead of print. https://doi.org/10.1007/s11906-022-01190-9
33. Shibayama Y, Wada N, Baba S, Miyano Y, Obara S, Iwasaki R, et al. Relationship Between Visceral Fat and Plasma Aldosterone Concentration in Patients With Primary Aldosteronism. J Endocr Soc 2018; 2(11):1236-1245. https://doi.org/10.1210/js.2018-00187
34. Shariq OA, McKenzie TJ. Obesity-related hypertension: a review of pathophysiology, management, and the role of metabolic surgery. Gland Surg 2020; 9(1):80-93. https://doi.org/10.21037/gs.2019.12.03
35. Oscullo G, Torres G, Campos-Rodriguez F, Posadas T, Reina-González A, Sapiña-Beltrán E, et al. Resistant/Refractory Hypertension and Sleep Apnoea: Current Knowledge and Future Challenges. J Clin Med 2019; 8(11):1872. https://doi.org/10.3390/jcm8111872
36. Khangura D, Kurukulasuriya LR, Sowers JR. Treatment of hypertension in diabetes: a contemporary approach with a focus on improving cardiovascular outcomes. Expert Rev Endocrinol Metab 2016; 11(1):41-50. https://doi.org/10.1586/17446651.2016.1130620
37. Viazzi F, Piscitelli P, Ceriello A, Fioretto P, Giorda C, Guida P, et al; AMD‐Annals Study Group. Resistant Hypertension, Time-Updated Blood Pressure Values and Renal Outcome in Type 2 Diabetes Mellitus. J Am Heart Assoc 2017; 6(9):e006745. https://doi.org/10.1161/JAHA.117.006745
38. Okonofua DE, Asiwe JN, Anachuna KK, Moke EG, Sanusi KO, Adagbada EO, et al. Effect of Diabetes Mellitus and Hypertension on Osmotic Fragility and Hemorheological Factors in Male Wistar Rats. Biol Med Natural Prod Chem 2021; 10(2):73-79. https://doi.org/10.14421/biomedich.2021.102.73-79
39. Basile JN, Bloch MJ. Identifying and managing factors that interfere with or worsen blood pressure control. Postgrad Med 2010; 122(2):35-48.
40. Hwang AY, Dave CV, Smith SM. Use of Prescription Medications That Potentially Interfere With Blood Pressure Control in New-Onset Hypertension and Treatment-Resistant Hypertension. Am J Hypertens 2018; 31(12):1324-1331. https://doi.org/10.1093/ajh/hpy118
41. Hunter RW, Ivy JR, Bailey MA. Glucocorticoids and renal Na+ transport: implications for hypertension and salt sensitivity. J Physiol 2014; 592(8):1731-44. https://doi.org/10.1113/jphysiol.2013.267609
42. Brar SK, Perveen S, Chaudhry MR, AlBabtain S, Amreen S, Khan S. Erythropoietin-Induced Hypertension: A Review of Pathogenesis, Treatment, and Role of Blood Viscosity. Cureus 2021; 13(1):e12804.
43. Stirratt MJ, Dunbar-Jacob J, Crane HM, Simoni JM, Czajkowski S, Hilliard ME, et al. Self-report measures of medication adherence behavior: recommendations on optimal use. Transl Behav Med 2015; 5(4):470-82. https://doi.org/10.1007/s13142-015-0315-2
44. Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, et al; American Heart Association Professional/Public Education and Publications Committee of the Council on Hypertension; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Genomic and Precision Medicine; Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research; and Stroke Council. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension 2018; 72(5):e53-e90. https://doi.org/10.1161/HYP.0000000000000084
45. de la Sierra A. Profile of ambulatory blood pressure in resistant hypertension. Hypertens Res 2013; 36(7):565-9. https://doi.org/10.1038/hr.2013.39
46. O'Shea PM, Griffin TP, Denieffe S, Fitzgibbon MC. The aldosterone to renin ratio in the diagnosis of primary aldosteronism: Promises and challenges. Int J Clin Pract 2019; 73(7):e13353. https://doi.org/10.1111/ijcp.13353
47. Bazzano LA, Green T, Harrison TN, Reynolds K. Dietary approaches to prevent hypertension. Curr Hypertens Rep 2013; 15(6):694-702. https://doi.org/10.1007/s11906-013-0390-z
48. Gunaydin C, Bilge SS. Effects of Nonsteroidal Anti-Inflammatory Drugs at the Molecular Level. Eurasian J Med 2018; 50(2):116-121.
49. Richards JR. Beta-Blockers and Evidence-Based Guidelines for the Pharmacological Management of Acute Methamphetamine-Related Disorders and Toxicity. Pharmacopsychiatry 2018; 51(3):108. https://doi.org/10.1055/s-0043-118413
50. Afshari M, Alizadeh-Navaei R, Moosazadeh M. Oral contraceptives and hypertension in women: results of the enrolment phase of Tabari Cohort Study. BMC Women's Health 2021; 21:224. https://doi.org/10.1186/s12905-021-01376-4
51. Didion SP. Tacrolimus-induced hypertension: what's endothelial and hematopoietic FKBP12 got to do with it? Hypertension 2011; 57(6):1058-60. https://doi.org/10.1161/HYPERTENSIONAHA.111.172320
52. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al; American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117(25):e510-26. https://doi.org/10.1161/CIRCULATIONAHA.108.189141
53. Roush GC, Ernst ME, Kostis JB, Tandon S, Sica DA. Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects. Hypertension 2015; 65(5):1041-1046. https://doi.org/10.1161/HYPERTENSIONAHA.114.05021
54. Agarwal R, Sinha AD, Pappas MK, Ammous F. Chlorthalidone for poorly controlled hypertension in chronic kidney disease: an interventional pilot study. Am J Nephrol 2014; 39(2):171-82. https://doi.org/10.1159/000358603
55. Sica DA. Mineralocorticoid Receptor Antagonists for Treatment of Hypertension and Heart Failure. Methodist Debakey Cardiovasc J 2015; 11(4):235-9. https://doi.org/10.14797/mdcj-11-4-235
56. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 Evidence-Based guideline for the management of high blood pressure in adults: report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311:507-20. https://doi.org/10.1001/jama.2013.284427
57. Guerrero-García C, Rubio-Guerra AF. Combination therapy in the treatment of hypertension. Drugs Context 2018; 7:212531. https://doi.org/10.7573/dic.212531
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).